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Background: Extracts from the marine algae Cymopolia barbata have previously shown promising pharmacological
activity including antifungal, antitumor, antimicrobial, and antimutagenic properties. Even though extracts have
demonstrated such bioactivity, isolated ingredients responsible for such bioactivity remain unspecified. In this study,
we describe chemical characterization and evaluations of biological activity of prenylated bromohydroquinones
(PBQ) isolated from the marine algae C. barbata for their cytotoxic and chemopreventive potential.
Methods: The impact of PBQs on the viability of cell lines (MCF-7, HT29, HepG, and CCD18 Co) was evaluated
using the MTS assay. In addition, their inhibitory impact on the activities of heterologously expressed cytochrome
P450 (CYP) enzymes (CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, and CYP3A4) was evaluated using a fluorescent
assay.
Results: 7-Hydroxycymopochromanone (PBQ1) and 7-hydroxycymopolone (PBQ2) were isolated using liquid and
column chromatography, identified using 1 H and 13 C NMR spectra and compared with the spectra of previously
isolated PBQs. PBQ2 selectively impacted the viability of HT29, colon cancer cells with similar potency to the known
chemotherapeutic drug, fluorouracil (IC50, 19.82 ± 0.46 μM compared to 23.50 ± 1.12 μM, respectively) with impact
toward normal colon cells also being comparable (55.65 ± 3.28 compared to 55.51 ± 3.71 μM, respectively), while
PBQ1 had no impact on these cells. Both PBQs had potent inhibition against the activities of CYP1A1 and CYP1B1,
the latter which is known to be a universal marker for cancer and a target for drug discovery. Inhibitors of CYP1
enzymes by virtue of the prevention of activation of carcinogens such as benzo-a-pyrene have drawn attention as
potential chemopreventors. PBQ2 potently inhibited the activity of CYP1B1 (IC50 0.14 ± 0.04 μM), while both PBQ1
and PBQ2 potently inhibited the activity of CYP1A1 (IC50s of 0.39 ± 0.05 μM and 0.93 ± 0.26 μM, respectively).
Further characterizations showed partial noncompetitive enzyme kinetics for PBQ2 with CYP1B1 with a Ki of
4.7 × 10–3 ± 5.1 × 10–4 μM and uncompetitive kinetics with CYP1A1 (Ki = 0.84 ± 0.07 μM); while PBQ1 displayed
partial non competitive enzyme kinetics with CYP1A1 (Ki of 3.07 ± 0.69 μM), noncompetitive kinetics with CYP1A2
(Ki = 9.16 ± 4.68 μM) and uncompetitive kinetics with CYP1B1 (Ki = 0.26 ± 0.03 μM) .
Conclusions: We report for the first time, two isolated ingredients from C. barbata, PBQ1 and PBQ2, that show
potential as valuable chemotherapeutic compounds. A hydroxyl moiety resident in PBQ2 appears to be critical for
selectivity and potency against the cancer colon cells, HT29, in comparison to the three other malignant cell lines
studied. PBQs also show potency against the activities of CYP1 enzyme which may be a lead in chemoprevention.
This study, the first on isolates from these marine algae, exemplifies the value of searching within nature for unique
structural motifs that can display multiple biological activities.
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Cymopolia barbata (Linnaeus) V.Lamouroux (Dasycla-
daceae) is widespread in shallow waters and is seen cov-
ering rocks by the shorelines in tropical marine habitats.
Known to grow to about 10-cm high, these green algae
(Chlorophyta) have tufts at the end of their stems that
are lightly calcified. Extracts from this plant have previ-
ously shown significant pharmacological properties such
as antifungal, antitumor, antimicrobial, and antimuta-
genic activities [1-8]. Although the cymopols are known
halogenated natural products which have been isolated
from C. barbata, active ingredients responsible for the
displayed biological activities remain unspecified. In this
study, we investigated bioactivities of prenylated bromo-
hydroquinones (PBQ), cymopol-related metabolites
which are known to accumulate in C. barbata, and re-
port, for the first time, biological activities from single
ingredients isolated from this marine algae. Two of these
compounds namely, 7-Hydroxycymopochromanone
(PBQ1) and 7-hydroxycymopolone (PBQ2), shown in
Figure 1 were investigated for cytotoxicity against three
cancerous cell lines, one normal cell line, in addition to
their potential for chemoprevention via inhibition of
cytochrome P450 (CYP) 1 enzymes.
The CYP1 family of enzymes and in particular
CYP1B1 appears to be a universal molecular cancer mar-
ker and a target for drug discovery. Findings of the over-
expression of CYP1B1 in many tumor tissues compared
with normal surrounding cells have led to the search for
prodrugs reliant on CYP1B1 metabolism for the conver-
sion into cytotoxic therapeutics [9]. The modification in
the expression levels of CYP1B1 has been shown to
modulate tumor progression [10] and thus specific inhi-
bitors are expected to be of therapeutic/preventive bene-
fit. Further, the involvement of CYP1 enzymes in the
bioactivation of procarcinogens such as polycyclic aro-
matic hydrocarbons (PAHs), heterocyclic amines, aro-
matic amines, and nitro polycyclic hydrocarbons [11], in
addition to the biotransformation of anticancer drugs,
has stimulated research into inhibitors of CYP1 enzyme
activity [12,13]. Such inhibitors are thought to be poten-











Figure 1 General structures of polyisoprenylated
bromohydroquinones (PBQ1 and PBQ2) isolated from the
marine algae, C. barbata.CYP1B1 and CYP1A1 to metabolize PAHs to toxic
intermediates and/or decrease their ability to detoxify
cancer drugs. A number of natural products have been
found to be direct inhibitors of CYP1 enzymes, as well
as generate metabolites that are CYP inhibitors with
cytotoxic properties. In the study described in this art-
icle, PBQ2 demonstrated potent inhibition against
CYP1B1 activity, together with promising and specific
activity against the colon cancer cell line HT29. The
examination of a close structural relative, PBQ1, also




All chemicals for the MTS and CYP inhibition assays
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). All CYP substrates and metabolites were pur-
chased from Gentest Corporation (Worburn, MA, USA).
Cell lines and CYP microsomes
All cell lines along with their respective media and sup-
plements were purchased from ATCC (Manassas, VA,
USA). Escherichia coli membranes expressing human
CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, and
CYP2C19 co-expressed with CYP reductase were pur-
chased from Cypex Ltd. (Dundee, UK).
Cell culture and cytotoxicity assays
Cell lines (CCD18 Co, HepG2 and MCF-7) were main-
tained in ATCC-formulated Eagle’s Minimum Essential
Medium and HT29 was maintained in McCoy’s 5a Modi-
fied Medium supplemented with 10% fotal bovine serum
(Atlas; Fort Collins, CO, USA), 10 mM HEPES solution,
100 mML-glutamine penicillin streptomycin solution,
3 g/L glucose, and 1.5 g/L of sodium bicarbonate. Cells
were maintained at 37°C with 5% CO2 in Corning 75 cm
2
culture flasks. Cells were exposed to a given isolate or
known anticancer agent for 24 h. Following the appropri-
ate treatments, cell viability was evaluated using an MTS
assay according to the manufacturer’s instructions [14].
All assays were performed at least three times and were
monitored spectrophotometrically at 590 nm [15]. Cell
viability was recorded as percentage relative to vehicle
solvent-treated control.
CYP inhibition assays
The test compounds were evaluated for their ability to
inhibit the catalytic activity of human CYP1 enzymes by
means of high throughput fluorometric detection assays
conducted in 96-well microtitre plates as described else-
where [16,17]. 7-Ethoxyresorufin (ERes) was used as a
substrate for detecting activity of CYP1B1 and 7-ethoxy-
3-cyanocoumarin (CEC) was used as a substrate for both
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N-diethyl-N-methylamino)ethyl]-7-methoxy-4methyl-
coumarin (AMMC), 7-benzyloxy-4-trifluoromethylcou-
marin (BFC), and CEC were used as substrates for
CYP2D6, CYP3A4, and CYP2C19, respectively. The
reactions were monitored fluorometrically at 37°C, using
a Varian Cary Eclipse fluorescence spectrophotometer.
All inhibitors were dissolved in a solvent of 20% aceto-
nitrile in water and less than 0.3% of acetonitrile was
used in the final assay.
Data analysis
IC50 and Ki values were determined by fitting the data in
Sigma Plot (version 10.0) and enzyme kinetics module,
using nonlinear regression analysis. The apparent Ki
values were determined on the basis of visual inspection
of Eadie-Hofstee and various statistics to evaluate good-
ness of fit, such as the size of the sum of squares of resi-
duals, Akaike information criterion, and standard error
(Enzyme kinetics module, version 1.3). The data listed
represent the average values from three different
determinations.
Results and discussion
Two PBQs (Figure 1) were isolated from the marine alga
C. barbata and investigated for biological activity. The
ability of these compounds to interfere with the reduc-
tion of the tetrazolium salt in the MTS assay was exam-
ined as a measure of impact on cell viability (Figure 2)
using normal and cancer colon cells (CCD18 Co and
HT29, respectively) along with liver and breast cancer
cells (HepG2 and MCF-7, respectively). IC50 values wereA
Figure 2 Percentage cell viability of colon cancer cells (HT29; A) and
known chemotherapeutic drug fluorouracil.calculated for test compounds and positive control
known drug entities, doxorubicin, fluorouracil, and tam-
oxifen (Table 1). PBQ2 selectively impacted the viability
of colon cells, HT29 with comparable potency to fluor-
ouracil (for HT29 cancer cells: IC50, 19.82 ± 0.46 μM
compared to 23.50 ± 1.12 μM and normal colon cells,
CCD18 Co IC50, 55.65 ± 3.28 compared to 55.51
± 3.71 μM, respectively). PBQ1 had no significant impact
(<10% at 60 μM) on any of the cell lines tested.
To verify the accuracy of experimental techniques
employed to detect CYP inhibition, assays with known
inhibitors were carried out with furafylline (against
CYP1A2 activity), ketoconazole (against activities of
CYP1A1, CYP1B1, and CYP3A4), (−)-N-3-Benzyl-
phenobarbital (against 2 C19) and quinidine (against
CYP2D6 activity) and the obtained IC50 values (0.8 ± 0.2,
0.04 ± 0.01, 6.3 ± 1.7, 0.06 ± 0.01, 0.3 ± 0.01, 0.03 ±
0.01 μM, respectively) compared well with published
values (0.99, <10, <10, 0.06, 0.25, and 0.04 μM, respect-
ively; [17-20]). Michaelis constant, KM, was determined
for each marker substrate under the specified experi-
mental conditions, in order to determine suitable sub-
strate concentrations for assessing inhibitory potential of
test compounds [21].
Both PBQs 1 and 2 potently (IC50 < 1 μM) inhibited
the activity of CYP1A1 (IC50s of 0.39 ± 0.05 and 0.93 ±
0.26 μM, respectively). PBQ2 also potently inhibited the
activity of CYP1B1 (IC50, 0.14 ± 0.04 μM) as shown in
Figure 3. For those interactions yielding an IC50 < 10 μM
against the activities of CYP1 family, further kinetic
characterization was carried out to determine the nature
of the inhibition, and Eadie-Hofstee plots are illustratedB
normal colon cells (CCD18 Co; B) in the presence of PBQ2 and
Table 1 IC50 values (µM) obtained from the interaction of
isomers of PBQs with colon cancer cell line (HT29) and
the normal colon cell line (CCD18Co) along with positive
controls
Compound Cell lines
CCD18 Co HT29 HepG MCF-7
PBQ1 NI NI NI NI
PBQ2 55.65 ± 3.28 19.82 ± 0.46 NI NI
Tamoxifen NA NA NA 17.28 ± 0.06
Fluorouracil 55.51 ± 3.71 23.50 ± 1.12 ND ND
Doxorubicin NA NA 18.61 ± 0.58 NA
Key NI, no impact (<10% inhibition at 60 μM); NA, not applicable; ND, not
determined.
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PBQ1 with partial noncompetitive inhibition of CYP1A1
activity, noncompetitive inhibition of CYP1A2 activity
(Kis of 3.07 ± 0.69 and 9.16 ± 4.68 μM, respectively) and
uncompetitive inhibition of CYP1B1 activity (Ki of 0.26
± 0.03 μM). PBQ2 displayed uncompetitive inhibition of
the activity of CYP1A1 (Ki of 0.84 ± 0.07 μM) and partial
noncompetitive inhibition of the activity of CYP1B1
(Ki of 4.7 × 10
–3 ± 5.1 × 10–4 μM).
Further characterization of the isolated test com-
pounds against other major drug metabolizing P450
enzymes (CYP2C19, CYP2D6, and CYP3A4) was carried
out. A summary table with all IC50 data is presented in
Table 2. As seen therein, while both PBQs 1 and 2 mod-






























Figure 3 Inhibition of activities of CYP isoforms by PBQs 1 (A) and PB
(0.37 μM), CYP1A1, CYP1A2, and CYP2C19-catalyzed dealkylation of CEC (0.5
(1.5 μM) and CYP3A4-catalyzed debenzylation of BFC (50 μM) were determ
between 0 and 900 μM, as described in the section “methods”. Control enz
CYP2D6, and CYP3A4 was 0.34 ± 0.08, 0.23 ± 0.04, 0.86 ± 0.01, 0.25 ± 0.02, 0.1
expressed as mean percentage of control enzyme activity for three indepe(IC50s, 1.03 ± 0.40 and 2.75 ± 0.96 μM, respectively) and
CYP3A4 (IC50s, of 5.07 ± 3.54 and 8.31 ± 4.67 μM,
respectively). PBQ1 and PBQ2 potently inhibited the ac-
tivity of CYP2C19 (0.08 ± 0.03 and 0.12 ± 0.06 μM,
respectively).
From the panel of cell lines tested, the impact on the
viability of malignant colon (HT29) and normal colon
(CCD18 Co) cells by PBQ2 was similar to that imparted
by the chemotherapeutic drug, fluorouracil, with com-
parable IC50 values. PBQ2 also displayed selective cyto-
toxicity toward HT29 cells with no impact on cancerous
liver (HepG2) and breast (MCF-7) cells. PBQ1, its struc-
tural isomer on the other hand, had no impact on any of
the cell lines investigated and thus the presence of a ter-
tiary hydroxyl group on PBQ2 appears to be critical for
the observed bioactivity. Be it the formation of hydrogen
bonds with key residues within the cell or during
receptor-mediated cell permeability, the conjugated,
open ring, and hydroxyl group presence in PBQ2 plays a
crucial role in impacting cell viability compared with
epoxy moiety of PBQ1.
Inhibitors of CYPs1A1 and 1B1 enzymes have received
particular interest due to their role in reducing the
activation of carcinogens and thus as chemoprotectors
and chemotherapeutics. Several classes of natural com-
pounds [22], including flavonoids [23,24] and organosul-
fur compounds [13,25,26], have demonstrated great
potential in chemoprevention and thus provide the im-
petus for the search for others. Both PBQs potently (IC50




























Q2 (B). Human recombinant CYP1B1-catalyzed dealkylation of ERes
, 5, and 25 μM, respectively) CYP2D6-catalyzed dealkylation of AMMC
ined in the presence of varying concentrations of PBQs ranging
yme activity (mean ± SEM) for CYP1B1, CYP1A2, CYP1A1, CYP2C19,
0 ± 0.003, and 1.28 ± 0.07 μM/min/pmol of CYP, respectively. Data are
ndent experiments.
Rate (µmol/µg/min)/[Substrate] (µM)























































































































































Figure 4 Eadie-Hofstee plots for inhibition of activities of CYP1A1 (A), CYP1A2(B), and CYP1B1(C) by PBQ1 along with inhibition of
activities of CYP1A1 (D) and CYP1B1 (E) by PBQ2. CEC dealkylation catalyzed by recombinant CYP1A1 and CYP1A2 was determined in the
absence and presence of six different concentrations of PBQs along with ERes dealkylation catalyzed by recombinant CYP1B1. Each point
represents the mean ± SEM of three independent experiments.
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Table 2 IC50 values (µM) obtained from the interaction of isomers of PBQs with CYP enzymes
Compounds CYP I isoforms
1A1 1A2 1B1 2 C19 2D6 3A4
PBQ1 0.39 ± 0.05 9.75 ± 0.0365 1.42 ± 0.14 0.08 ± 0.03 1.03 ± 0.40 5.07 ± 3.54
PBQ2 0.93 ± 0.26 10.55 ± 6.75 0.14 ± 0.04 0.12 ± 0.06 2.75 ± 0.96 8.31 ± 4.67
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out mice models have linked CYP1B1 with the activation
of several carcinogens, such as B[a]P and DMBA [11]
and have also been shown to play an important role in
modulating tumor progression [10,27]. Thus, the potency
toward both CYP1B1 and CYP1A1 activities by PBQ2
suggests potential chemopreventive bioactivity in vivo.
Conversely, PBQ1 with demonstrated CYP1A1 inhibition,
devoid of cytotoxicity on all cells examined in this study,
also highlights it as an attractive candidate with potential
for development as a chemoprotector.
The development of novel classes of therapeutics that
can target both drug metabolizing enzymes and disease
pathways is a multi-targeted approach that may well suit
the multi-factorial origins of a disease such as cancer.
Examples of such compounds include isothiocyanate
which impact both Nrf-2 transcription factors, and inhibit
the nuclear factor ĸß pathway to exhibit potent anti-
inflammatory properties [28]. Such attractive dual qual-
ities are displayed by PBQ2 in this study, with potent and
selective targeting of HT29 colon cancer cells, as well as
the inhibition of CYP1A1 and CYP1B1enzyme activities.
The potency of PBQ2 can be put into perspective with
the reported inhibitory effect of eight flavonoids tested
against recombinant human CYP1B1 and CYP1A1 en-
zyme activities which showed a range in IC50s between
0.3 and 27 μM [29]. They made ideal chemoprotectants
against prostate cancer [30]. PBQ2 had an IC50 of
0.14 μM, which appears to be more potent at inhibiting
CYP1B1 activity than all the eight flavonoids tested by
Chaudhary and Willet [29], making this isolate an ideal
candidate for further research.
PBQs examined in this study displayed reversible, non
or uncompetitive (partial or full) kinetics on CYP1 en-
zyme activities. In noncompetitive inhibition, typically
the IC50 value is equal to the Ki, while in uncompetitive
inhibition IC50 will equal twice the value of the Ki for
experiments where the substrate concentration is close
to the Km value [31], as designed in our experiments.
Such approximations are observed in the kinetics of
PBQ1 with CYPs1A2, 1B1 and of PBQ2 with CYP1A1,
although deviations from these approximations were
seen for interactions of PBQ1 with CYP1A1 and PBQ2
with CYP1B1 where the partial noncompetitive kinetics
were observed and such mixed type binding may com-
plicate relations between IC50 and Kis. Due to the non
and uncompetitive nature of PBQ binding with CYP1A1,previous active site models developed for CYP1A1 using
natural product quassinoids [20,32], were therefore not
useful in shedding light on structure–activity relation-
ships within the active site. The dietary flavonoid, galan-
gin, shown to display inhibition of DMBA-induced
CYP1A1 in MCF-7 breast cancer cells, was of a non-
competitive, dose-dependent manner [33] similar to that
of PBQ1.
Investigating the impact of these PBQs against the
other major drug metabolising enzymes (CYP2C19,
CYP2D6, and CYP3A4) allowed for the predictions of
drug interaction potential. The impacts on CYP3A4 and
CYP2D6, the enzymes responsible for metabolism of
over 90% of drugs on the market, were only moderate by
the two PBQs, suggesting unlikely metabolism-based
drug interactions via these important enzymes. However,
both compounds potently inhibited CYP2C19 activity.
CYP2C19 is also involved in the process of carcinogen-
esis albeit with lower impact than the CYP1 family, and
the CYP2C19 inhibition by the PBQs may prove useful
in chemopreventive value, although drug interactions
possibility via this enzyme that metabolises important
therapeutics such as omeprazole and theophylline will
remain a concern compounded by likely variations in in-




Cymopolia barbata was collected from the shoreline of
the north eastern coast of Jamaica at Fairy Hill Beach in
the parish of Portland at a depth of 0.5 m in June 2004.
A voucher specimen (#UWI-Mona 35, 438) was depos-
ited in the Herbarium at the University of the West
Indies, Mona, Jamaica.
Extraction and isolation
The air-dried sample (962.15 g) was extracted with
methanol:dichloromethane (1:1) to yield a dark green
gum (30.91 g), a portion of which (12.8 g) was subjected
to vacuum liquid chromatography on silica gel in a 2-L
sintered funnel with a gradient elution system consisting
of increasing proportions of CH2Cl2 in hexanes, 100%
CH2Cl2 with final elution in 20% methanol:CH2Cl2. Of
the 56 fractions obtained, fraction 22–24 (2.35 g), which
eluted in 20% methanol:CH2Cl2, underwent further grav-
ity column chromatography to afford 172 sub fractions.
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tain 7-hydroxycymopochromanone (PBQ1). Another
portion of the crude extract (2.0130 g) was subjected to
column chromatography on a Sephadex LH-20 column
in methanol resulting in 11 main combined fractions.
The fifth combined fraction from this column was sub-
jected to silica gel chromatography in 30% acetone:hex-
ane to afford 37 fractions. Fraction 23–28 was found to
contain 7-hydroxycymopolone (PBQ2). Both PBQs were
identified by comparison of their 1 H and 13 C NMR data
with the literature [1,34].
NMR data for 7-hydroxycymopochromanone (PBQ1)
1 H NMR(CDCl3, ppm): 1.05, 3 H, s (H-8), 1.20, 3 H, s
(H-9), 1.30, 2 H, m (H-6), 1.35, 3 H, s (H-10), 1.61, 2 H,
m (H-4), 1.61, 2 H, m (H-5), 2.99, 1 H, s (H-2), 3.00,
1 H, s (H-2), 5.35, 1 H, br s (OH-60), 7.13, 1 H, s (H-40),
7.66, 1 H, s (H-10), 12.00, 1 H, s (OH-7).
13 C NMR (CDCl3, ppm): 16.3 (C-5), 27.1 (C-10), 28.2
(C-8), 32.2 (C-9), 34.5 (C-4), 36.3 (C-6), 52.7 (C-2), 72.2
(C-7), 73.9 (C-3), 118.3 (C-10), 118.8 (C-50), 120.8 (C-40),
121.1 (C-20), 144.2 (C-60), 156.1 (C-30), 205.4 (C-1).
NMR data for 7-hydroxycymopolone (PBQ2) 1 H
NMR (CDCl3, ppm):1.28, 6 H, s (H-8, 9), 1.55, 2 H, m
(H-6), 1.67, 2 H, m (H-5), 2.20, 3 H, s (H-10), 2.30 2 H,
t, J = 7.5 Hz (H-4), 6.69, 1 H, s (H-2), 7.18, 1 H, s (H-40),
7.43, s (H-10), 12.32, 1 H, s (OH-7).
13 C NMR (CDCl3, ppm): 20.5 (C-10), 22.6 (C-5), 29.7
(C-8), 29.7 (C-9), 42.3 (C-4), 43.5 (C-6), 71.5 (C-7), 115.6
(C-10), 119.0 (C-50), 119.8 (C-2), 120.9 (C-20), 121.9 (C-
40), 145.0 (C-60), 157.2 (C-30), 162.6 (C-3), 195.9 (C-1).
Conclusions
The polyisoprenylated bromohydroquinone, PBQ2, was
found to affect cell viability of colon cells (HT29) com-
parable to the chemotherapeutic drug fluorouracil, with
selectivity, making this compound an ideal lead candi-
date suitable for further experimentation in chemother-
apy of colon cancer cells. In addition, it showed potent
inhibition against CYP1B1 enzyme activities, a marker
for cancer and target for drug discovery. Compounds
such as PBQ2 that can target both drug metabolizing
enzymes and disease state cells are of high value. Such
chemotherapeutic and chemopreventive potential im-
plied by the displayed bioactivity validate the on-going
search for treatment leads among natural products from
endemic tropical biodiversity including marine habitats.
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